Metabolex CEO to Be Featured on BIO Investor Diabetes Panel Today
Posted on: Thursday, 19 October 2006, 09:01 CDT
HAYWARD, Calif., Oct. 19 /PRNewswire/ -- Metabolex, Inc., a biotechnology company dedicated to the discovery and development of novel therapeutics for diabetes and related metabolic disorders, announced today the President and Chief Executive Officer Harold Van Wart, Ph.D. will be featured on a panel at the annual BIO InvestorForum meeting in San Francisco today.
The session, "The Impact of Research on the Growing Diabetes Epidemic," will be held at 3:30 p.m. in the Telegraph room of the Palace Hotel.
About Metabolex
Metabolex is a privately held biotechnology company dedicated to the discovery and development of novel therapeutics to transform the treatment of diabetes and related metabolic disorders. Metabolex has drawn on its deep understanding of diabetes to create the largest database of genes involved in diabetes and to build a rich pipeline of product candidates and drug discovery targets. The company's clinical program is focused on developing next- generation insulin sensitizers that lower blood glucose without the serious safety and tolerability issues associated with currently marketed products. Metabolex is partnering with Ortho-McNeil, a Johnson & Johnson company, to develop and commercialize products for diabetes and metabolic disease, including Metabolex's lead drug candidate, metaglidasen, a second-generation insulin sensitizer now in a Phase 2/3 clinical trial. For additional information about Metabolex and its development pipeline, visit http://www.metabolex.com/.
Metabolex, Inc.
CONTACT: Mark Bagnall of Metabolex, +1-510-293-8800 ormbagnall@metabolex.com; or Brian Reid of WeissComm Partners, +1-703-402-3626or breid@weisscommpartners.com, for Metabolex
Web site: http://www.metabolex.com/
Source: PRNewswire
Related Articles
- Sorrento Therapeutics Announces Antibody Discovery and Development Alliance for the Prevention and Treatment of MRSA Infections
- Catalyst Biosciences Expands Scientific Advisory Board With Leading Experts in Protease Therapeutic Discovery and Development
- Advinus Therapeutics (P) Ltd. And Ortho-McNeil-Janssen Pharmaceuticals, Inc. Establish Drug Discovery and Development Collaboration
- VistaGen CEO to Present Overview of Recent Stem Cell-Based Drug Discovery and Development Advances at Society of Biomolecular Sciences Symposium
- Icagen Announces New Members of Drug Discovery and Development Expert Panel
- Accelrys to Release SciTegic Pipeline Pilot(TM) 6.0, the Scientific Operating Platform for Discovery and Development
- Incyte Announces First Quarter Financial Results and Provides Update on Drug Discovery and Development Programs
- ViroLogic Announces Multi-Year Service Agreement With Schering-Plough to Support New HIV Drug Discovery and Development Efforts
- Nicotinic Acid in the Management of Dyslipidaemia Associated With Diabetes and Metabolic Syndrome: a Position Paper Developed By a European Consensus Panel
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds